Company / Working Capital
Denali Therapeutics Inc. Working Capital History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$802.3M
FY2025
5-year range
$519.0M / $1.0B
FY2021-FY2025
Trend
+5.3%
vs FY2024
Sector context
#49 of 213
Health Care
What the data says
Denali Therapeutics Inc.'s working capital of $802M is higher than 77% of companies in the Health Care sector (FY2025). Working Capital returned to growth in FY2025 after 2 years of decline, reaching $802M.
Based on SEC 10-K filings.
$802M in FY2025 with a 5-year CAGR of -10.8%. Top quartile in the Health Care sector.
Declined from $986M to $802M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -7.3%
- 5-Year CAGR
- -10.8%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 213This company $802.3M Sector average $934.6M
▼
-14.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -10.8%, indicating a declining trend.
- In FY2025, working capital increased 5.3% year-over-year.
- Ranks #49 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $802.3M | +5.3% |
| FY2024 | $762.2M | -22.7% |
| FY2023 | $986.2M | -2.2% |
| FY2022 | $1.0B | +94.3% |
| FY2021 | $519.0M | -63.6% |
| FY2020 | $1.4B | +270.2% |
| FY2019 | $384.7M | -14.1% |
| FY2018 | $448.1M | +13.3% |
| FY2017 | $395.4M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026